Oncology Medications

Nerlynx (neratinib)

Your Pharmacy for Nerlynx

NERLYNX™ (neratinib) is approved for patients with HER2+ early stage breast cancer. NERLYNX is a limited distribution oral oncology medication, which means it is not available from most pharmacies.  Due to our oncology focus, and extensive experience handling oral oncology medications, Onco360 has been selected as one of the handful of pharmacies across the country that can dispense NERLYNX.

According to the National Cancer Institute (NCI), 252,710 women will be diagnosed with breast cancer in 2017. Approximately 20% of all breast cancers are histologically HER2-positive. Due to the aggressive nature of this subtype of breast cancer, about 26% of patients will have a recurrence of cancer despite trastuzumab-based therapy.  

NERLYNX, an orally-available tyrosine kinase inhibitor, has been granted approval by the FDA for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. See Full Prescribing Information1

Put the Oncology Pharmacy experts at Onco360 to work for your breast cancer patients today.

How to Refer

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis



1NERLYNX Prescribing Information: Puma Biotechnology 2017. NERLYNX is a registered trademark of Puma Biotechnology, Inc.